Segway Powersports Unveils MY27 Lineup and iFUN 2.0 at EICMA 2026, Outlines Global Growth Plans

MILAN, Nov. 4, 2026 /PRNewswire/ -- Segway Powersports unveiled its Model Year 2027 (MY27) lineup and next-generation iFUN 2.0 connected system at EICMA 2026. Alongside upgraded ATVs, a flagship two-row UTV and new connected technologies, the company outlined plans to expand its global dealer and service networks.

AT6 Pro: More Power, Sharper Control

The MY27 AT6 Pro is a key performance model in the lineup. Powertrain and handling improvements give riders more power and greater control. Its 606cc engine, paired with a CVTech transmission, now produces 49 hp. Overall powertrain performance has improved by approximately 15%. To help riders harness that power, electronic throttle control and selectable riding modes allow them to tailor power delivery to changing terrain.

AT10: Flagship Power and Performance

Built for powerful acceleration and demanding off-road rides, the MY27 AT10 is Segway Powersports' flagship ATV. Its in-house-developed 999cc parallel-twin DOHC engine produces 97 hp and 92 N•m of torque, powering the vehicle from 0 to 100 km/h in eight seconds. Precise valve control supports strong performance at high engine speeds, while the engine's low-vibration design helps keep longer rides comfortable. The AT10 also features iFUN2.0 for a more connected riding experience.

UT10 Crew Pro: All-Weather Comfort, Every Adventure

The UT10 Crew Pro is Segway Powersports' flagship two-row UTV. Its fully enclosed cabin combines automotive-grade sealing with double-layer door seals to help keep dust, moisture and outside noise at bay. Inside, a heating, ventilation and air conditioning (HVAC) system keeps the cabin comfortable. Whether working outdoors or exploring trails with family and friends, drivers and passengers can enjoy a comfortable ride. Steering-wheel controls and iFUN 2.0 put vehicle functions within easy reach.

SX20T: Putting Performance to the Test

Powered by a 2.0-liter turbocharged engine producing 235 hp, the SX20T is a high-performance sport side-by-side. The model's racing potential was put to the test in multiple competitions worldwide.

In 2026, the SX20T made its debut at two major U.S. off-road races: King of the Hammers in February and the Mint 400 in March, finishing third in its group at the latter. In May, it placed second in the T3-N class on the SS2 stage of South America's Desafío Ruta 40, a rally known for its demanding terrain. In Europe, it secured a third-place finish in the SSV category at Portugal's Baja Portalegre 500 in October.

At an EICMA ceremony, Segway Powersports also announced its first-ever brand ambassadors: André Rodrigues, Mathias Bellino, Richard Mosna, Nikola Vujnović and Lycett Dayne Christopher. Their experience racing Segway ATVs and SSVs at events worldwide showcases the brand's off-road expertise and vehicle performance.

iFUN 2.0: A Smarter, More Connected Ride

Developed in-house, iFUN 2.0 brings together six core technologies to simplify vehicle access and control, from preparing for a ride to navigating the trail.

Before setting off, riders can check vehicle information through smartphone connectivity and access the vehicle without a physical key using keyless entry. Digital-key sharing lets owners extend that access to family members or riding partners.

On the trail, transparent chassis technology reveals the ground beneath the vehicle, helping riders spot obstacles and navigate uneven terrain. Voice control and fingertip controls keep vehicle functions easy to operate, while Bluetooth intercom support lets two riders stay in touch through their helmets.

Both the AT10 and UT10 Crew Pro are equipped with iFUN 2.0.

Strengthening Global Reach

Segway Powersports' global sales network spans more than 65 countries and regions, with over 1,300 retail locations and flagship stores in markets including Spain, Saudi Arabia and Argentina. Building on this presence, the company plans to expand its dealer and service networks to better support customers and dealers worldwide.

At EICMA, Segway Powersports will host its biennial global dealer summit, bringing together dealers and distribution partners from around the world to strengthen partnerships and explore new opportunities for growth.

The refreshed lineup, in-house-developed technologies and global growth goals reflect Segway Powersports' commitment to enhancing performance, pushing boundaries and inspiring exploration. Together, they embody the brand's "Fear No Place" philosophy and empower riders to go further and conquer new terrain.

Beyond performance, Segway Powersports is also forging a distinct visual identity anchored by Rider Red——its signature color-paired with the dedicated Segway Powersports logo. Consistently applied across vehicle designs and brand materials, the color creates a bold, instantly recognizable brand presence.

About Segway Powersports

Segway Powersports is Segway's professional-grade, high-performance powersports line for global markets. Its vehicles combine power, strong torque, durability and responsive handling for diverse and demanding terrain. The brand operates in more than 65 countries and regions, with over 1,300 retail locations and flagship stores in markets including Spain, Saudi Arabia and Argentina.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Segway Powersports Unveils MY27 Lineup and iFUN 2.0 at EICMA 2026, Outlines Global Growth Plans

Segway Powersports Unveils MY27 Lineup and iFUN 2.0 at EICMA 2026, Outlines Global Growth Plans

Segway Powersports Unveils MY27 Lineup and iFUN 2.0 at EICMA 2026, Outlines Global Growth Plans

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system

SINGAPORE, Nov. 5, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.

The study marks an important and planned transition from studying genomics primarily in healthy volunteers to studying those with a broad range of medical conditions. By connecting genomic information with real-world health data, SG-INSIGHT aims to better understand disease and treatment responses, support the responsible introduction of genetic screening in Singapore's public healthcare system, and help healthcare become more tailored to individuals over time.

"Singapore is showing what the future of precision medicine can look like at national scale," said Jacob Thaysen, Chief Executive Officer of Illumina. "By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease, generate evidence that support more informed care decisions, and ultimately move healthcare toward earlier, more precise intervention. We are proud to bring Illumina's technology, expertise and longstanding presence in Singapore to help make that vision possible."

"Phase III builds on nearly a decade of precision medicine in Singapore," said Professor Patrick Tan, Executive Director of PRECISE. "By extending the programme to patients across the public healthcare system, SG-INSIGHT aims to deepen understanding of how genetic, lifestyle and environmental factors are associated with health and disease. Phase III reflects Singapore's ambition to build a trusted and sustainable precision health ecosystem grounded in the needs and diversity of its population."

Illumina will perform the sequencing in Singapore through its local genomics facility where scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing, and genomic data analysis. Co-located with Illumina's manufacturing and R&D operations, the facility will seek the necessary accreditation and comply with Singapore's Healthcare Services Act 2020 (HCSA), strengthening its commitment to quality, safety, regulatory compliance and biomedical innovation. 

Illumina's selection for the SG-INSIGHT Study was awarded through an international competitive tender. It builds on an existing multi-year engagement, through which Illumina supported the successful implementation and delivery of NPM Phase II, PRECISE-SG100K, covering more than 100,000 genomes from healthy volunteers.

"For nearly two decades, Singapore has been one of Illumina's most important centres for innovation, manufacturing and talent in Asia Pacific," said Nilesh Shah, Head of Region, Asia Pacific, Illumina. "Our long-standing relationship with PRECISE represents the next chapter in that commitment - combining Singapore's leadership in precision health with Illumina's local genomic capabilities and regional expertise. We remain committed to investing in the people, technology and partnerships that can help advance genomics responsibly in Singapore and across the region."

Illumina established its presence in Singapore in 2008. Today, Singapore serves as the company's Asia Pacific regional headquarters and one of its largest hubs outside the United States, with more than 1,700 employees across three locations. Illumina operations in Singapore encompass commercial operations, manufacturing, and R&D, supporting global research and innovation across sequencing platforms, software, and emerging technologies.

About PRECISE

Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore's multi-phase National Precision Medicine (NPM) programme. Established to drive a whole-of-Singapore effort, PRECISE works with research, clinical and industry partners to generate insights into Asian genomics and translate these into better health outcomes and economic opportunities.

PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore. NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734).

www.npm.sg

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Illumina selected to help bring precision medicine into everyday healthcare in Singapore